Biotechnology Assets S.A. (BST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotechnology Assets S.A. (BST) has a cash flow conversion efficiency ratio of 0.102x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€658.13K ≈ $769.43K USD) by net assets (€6.45 Million ≈ $7.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BST market cap for the company's overall valuation and market capitalisation.
Biotechnology Assets S.A. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Biotechnology Assets S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biotechnology Assets S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotechnology Assets S.A. ranked by their cash flow conversion efficiency. Explore Biotechnology Assets S.A. (BST) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SolTech Energy Sweden AB
ST:SOLT
|
-0.008x |
|
Tomypak Holdings Bhd
KLSE:7285
|
-0.001x |
|
Powerhouse Ventures Ltd
AU:PVL
|
-0.030x |
|
Malpac Holdings Bhd
KLSE:4936
|
0.000x |
|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
-0.165x |
|
DeepMarkit Corp
V:MKT
|
-0.522x |
|
Dolphin Entertainment Inc
NASDAQ:DLPN
|
0.060x |
|
M Cash Integrasi Tbk PT
JK:MCAS
|
-0.044x |
Annual Cash Flow Conversion Efficiency for Biotechnology Assets S.A. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Biotechnology Assets S.A. from 2014 to 2024. View BST share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €6.61 Million ≈ $7.73 Million |
€-73.85K ≈ $-86.34K |
-0.011x | -252.87% |
| 2023-12-31 | €6.53 Million ≈ $7.64 Million |
€47.74K ≈ $55.81K |
0.007x | +101.63% |
| 2022-12-31 | €3.87 Million ≈ $4.53 Million |
€-1.73 Million ≈ $-2.03 Million |
-0.447x | -29.25% |
| 2021-12-31 | €4.34 Million ≈ $5.07 Million |
€-1.50 Million ≈ $-1.76 Million |
-0.346x | -115.13% |
| 2020-12-31 | €3.84 Million ≈ $4.49 Million |
€8.79 Million ≈ $10.28 Million |
2.288x | +214.10% |
| 2019-12-31 | €7.56 Million ≈ $8.84 Million |
€-15.16 Million ≈ $-17.72 Million |
-2.005x | -226.35% |
| 2018-12-31 | €21.19 Million ≈ $24.78 Million |
€-13.02 Million ≈ $-15.23 Million |
-0.614x | -2410.54% |
| 2017-12-31 | €8.03 Million ≈ $9.38 Million |
€213.49K ≈ $249.59K |
0.027x | -92.21% |
| 2016-12-31 | €7.96 Million ≈ $9.30 Million |
€2.71 Million ≈ $3.17 Million |
0.341x | +1533.30% |
| 2015-12-31 | €7.57 Million ≈ $8.85 Million |
€158.16K ≈ $184.90K |
0.021x | +152.79% |
| 2014-12-31 | €7.68 Million ≈ $8.97 Million |
€-303.79K ≈ $-355.16K |
-0.040x | -- |
About Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more